News
-
-
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU for young children with chronic spontaneous urticaria, expanding treatment options to address type 2 inflammation -
-
PRESS RELEASE
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Sanofi's lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP, showing promising results for managing respiratory diseases -
-
PRESS RELEASE
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Positive results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented at AAD Annual Meeting, showing progressive efficacy with Q12W dosing potential -
-
-
PRESS RELEASE
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
Sanofi's Sarclisa subcutaneous formulation via on-body injector recommended for EU approval by CHMP for multiple myeloma treatment, offering innovative delivery. Final decision expected soon
